share_log

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

HC Wainwright & Co.維持對X4製藥的買入,將目標股價上調至5美元
Benzinga ·  04/30 06:52

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $3 to $5.

HC Wainwright & Co. 分析師Swayampakula Ramakanth維持X4製藥公司(納斯達克股票代碼:XFOR)的買入並將目標股價從3美元上調至5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論